Abstract
Overactivity of the noradrenergic (NE) system within the central nervous system (CNS) has been postulated as a key pathophysiology of posttraumatic stress disorder (PTSD). The activity of the enzyme salivary α-amylase (sAA) has been proposed as an indirect measure of CNS NE activity, and sAA is elevated in PTSD. As an antagonist of the α-1 NE receptor, prazosin would be expected to alter sAA values in PTSD patients. However, given its short half-life, it is not clear whether bedtime doses would have an effect on daytime sAA. In the present study, we assayed daytime sAA in 20 suicidal PTSD patients who were randomized to prazosin versus placebo at bedtime-only, and found no effect in daytime sAA. These findings are consistent with studies showing an advantage for twice daily dosing of prazosin in PTSD.
| Original language | English |
|---|---|
| Article number | e01709 |
| Journal | Heliyon |
| Volume | 5 |
| Issue number | 5 |
| DOIs | |
| State | Published - May 2019 |
Bibliographical note
Publisher Copyright:© 2019
Funding
This project was supported by the American Foundation for Suicide Prevention ; DIG-0-087-13 .
| Funders | Funder number |
|---|---|
| American Foundation for Suicide Prevention | DIG-0-087-13 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Psychiatry
ASJC Scopus subject areas
- General
Fingerprint
Dive into the research topics of 'Bedtime doses of prazosin do not affect daytime salivary amylase markers in PTSD'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver